Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents

Table 2

Hemoglobin response (hemoglobin increase >20 g/L or to ≥120 g/L; in the 2010 Auerbach trial target Hb ≥110 g/L), EOTP ferritin, and EOTP TSAT for the seven published RCTs comparing ESA ± iron supplementation.

Trial	Hemoglobin response (%)	EOTP ferritin (μg/L)	EOTP TSAT (%)
Auerbach 2004 [26]	25/36/68/68^a	NR	NR
Auerbach 2010 [31]	72/82^b	50/539^d	−0.4/6.7^d
Bastit et al. [29]	73/86^b	NR	NR
Hedenus et al. [28]	53/93^b	112/400^b	20/30^b
Henry et al. [27]	41/45/73^c	−96/−14/344^e	−14/−2.7/−1.8^e
Pedrazzoli et al. [30]	70/93^b	NR	NR
Steensma et al. [32]	65/67/70^c	372/426/726^c	24/28/24^c

^acontrol/p.o. iron/bolus doses iron/total dose infusion iron; ^bcontrol/i.v. iron; ^ccontrol/p.o. iron/i.v. iron; ^dmean change control/i.v. iron; ^emean change control/p.o. iron/i.v. iron. Abbreviations: EOTP, end of treatment period; TSAT, transferrin saturation; NR, not reported; i.v., intravenous.